AEMD
Aethlon Medical, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$1.82
−5.70%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.3x
Market Cap
$2.92M
MomentumView details →
1D Return
−5.70%
YTD Return
−87.40%
RSI (14)
28.3
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.3x
Market Cap
$2.92M
RSI (14)
28.3
MomentumView details →
1D Return
−5.70%
YTD Return
−87.40%
SummaryUpdated Jun 1, 2026
Aethlon Medical, Inc. (NASDAQ:AEMD) is a medical technology company founded in 1999 and based in San Diego, California. The company went public in March 1999 and focuses on developing innovative blood filtration devices to treat life-threatening diseases. Aethlon operates as a clinical-stage company with its flagship product, the Hemopurifier, currently undergoing various clinical trials for cancer treatment and viral infections. The company has no commercial revenue from product sales and remains in the research and development phase, funded primarily through equity raises and government contracts.
Similar companies
Latest newsMore news →
Aethlon Medical reported financial results for its fiscal first quarter ended June 30, 2026, and provided a corporate update on its Hemopurifier program.22d agoAethlon Medical priced a follow-on offering of 5,633,009 shares of common stock (or pre-funded warrants) and warrants at a combined public offering price of $0.7101 per share.60d ago